Brief: Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy
Thu 22:52
BRIEF-Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy Oct 22 (Reuters) - Vor Biopharma Inc. VOR.O:
TELITACICEPT DEMONSTRATES DURABLE PRESERVATION OF KIDNEY FUNCTION THROUGH TWO YEARS IN PHASE 3 TELIGAN TRIAL IN IGA NEPHROPATHY
VOR BIOPHARMA - TELITACICEPT REDUCES RISK OF ≥30% EGFR DECLINE BY 89% AND ≥40% DECLINE BY 81%
VOR BIOPHARMA - NO KIDNEY FAILURE EVENTS IN TELITACICEPT GROUP; FIVE EVENTS IN PLACEBO INCLUDING TWO REQUIRING DIALYSIS
VOR BIOPHARMA - TELITACICEPT SUSTAINS PROTEINURIA REDUCTION THROUGH 104 WEEKS WITH FAVORABLE SAFETY PROFILE
Source text: ID:nGNX1LL6t0
Further company coverage: VOR.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Vor Biopharma
See all newsBrief: Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning